We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
UnitedHealth Q4 Earnings Beat on Strong Optum Rx, Offers 2026 Outlook
Read MoreHide Full Article
Key Takeaways
UNH beat Q4 EPS estimates as Optum Rx strength helped drive a 12% year-over-year revenue increase.
UNH saw profits fall as elevated medical costs pushed the medical care ratio sharply higher year over year.
UNH forecast 2026 EPS of at least $17.75 with improved margins, while revenue is expected to be below 2025.
UnitedHealth Group Incorporated (UNH - Free Report) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.11, which beat the Zacks Consensus Estimate of $2.09. However, the bottom line declined 69% year over year.
Revenues rose 12% year over year to $113.2 billion. The top line marginally missed the consensus mark.
The quarterly earnings were aided by growth in commercial fee-based membership and the strength witnessed in Optum Rx. However, elevated medical costs and declining risk-based membership partially offset the positives.
The proposed 0.09% increase for 2027 Medicare Advantage payments from CMS was below analyst expectations, which might dampen the effects of the earnings beat and the outlook for 2026.
For the full-year 2025, revenues increased almost 12% year over year to $447.6 billion, but marginally missed the consensus mark. Adjusted earnings of $16.35 per share declined from $27.66 a year ago, but beat the consensus estimate by 0.3%.
UnitedHealth Group Incorporated Price, Consensus and EPS Surprise
UnitedHealth’s fourth-quarter premium of $88.8 billion increased from $76.5 billion a year ago but missed the consensus mark of $89 billion.
UNH’s adjusted medical care ratio (MCR) was 91.5% in the fourth quarter, which deteriorated 640 bps from the year-ago period. The metric was lower than the Zacks Consensus Estimate of 92.2%. MCR witnessed an increase due to reductions in Medicare funding and rising medical cost trend, which exceeded the pricing trend. Medical costs of $82 billion rose from $67 billion a year ago.
Fourth-quarter total operating costs of $112.8 billion escalated 21.3% year over year due to higher medical costs and operating costs. The figure came higher than our model estimate of $109.4 billion. The fourth-quarter 2025 adjusted operating cost ratio deteriorated to 13.5% from 11.9% a year ago.
UnitedHealth’s adjusted operating earnings declined 62.1% year over year to $3.1 billion in the fourth quarter.
UNH’s Business Platforms
Revenues of the health benefits business of UnitedHealth, UnitedHealthcare, advanced 17.5% year over year to $87.1 billion in the fourth quarter. The metric missed the Zacks Consensus Estimate of $87.3 billion. The UnitedHealthcare business catered to 49.8 million people as of Dec. 31, 2025, which grew 0.8% year over year. However, the figure missed the Zacks Consensus Estimate of 50.4 million.
Adjusted earnings from operations amounted to $472 million, down from $3 billion a year ago. The adjusted operating margin decreased to 0.5% from 4.1% a year ago.
Revenues in the Optum business line were $70.3 billion, which rose from $65.1 billion a year ago, due to strong contributions from Optum Rx. The figure surpassed the consensus mark of $67.6 billion. Optum’s adjusted earnings from operations declined to $2.7 billion from $5.2 billion a year ago. The adjusted operating margin of 3.8% decreased from 8%.
UNH’s Financial Position (As of Dec. 31, 2025)
UnitedHealth exited the fourth quarter with cash and short-term investments of $28.1 billion, which fell from the 2024-end level of $29.1 billion. Total assets of $309.6 billion increased from the $298.3 billion figure at 2024-end.
Long-term debt, less of current maturities, amounted to $72.32 billion, marginally down from the $72.36 billion figure as of Dec. 31, 2024. Short-term borrowings and the current maturities of long-term debt were $6.1 billion.
Total equity of $100.1 billion advanced from the 2024-end level of $98.3 billion.
UnitedHealth generated operating cash flows of $19.7 billion in 2025, which declined from the prior-year figure of $24.2 billion. For the full-year 2025, it made share repurchases worth $5.5 billion and paid dividends worth $7.9 billion.
UNH’s 2026 Outlook
Management projects revenues for 2026 above $439 billion, which is below the 2025 level due to planned right-sizing across operations. Adjusted EPS is expected to be at least $17.75 for 2026, indicating improving margins. It is higher than the Zacks Consensus Estimate of $17.61 now. Net margin is expected at around 3.6%, up from 2.7% in 2025.
It expects MCR to be 88.8% (± 50 bps) in 2026, down from 89.1% in 2025, while the operating cost ratio is likely to be 12.8% (± 50 bps). Tax rate is expected to be around 19.25%.
Operating cash flows are estimated to be $18 billion, down from the 2025 level. It expects to make repurchases of $2.5 billion and pay dividends worth $8 billion in 2026. Capex is estimated at $3.8 billion for the year.
Furthermore, it expects medical memberships to be within 46.945 – 47.495 million in 2026, with significant declines in commercial risk, Medicare Advantage and Medicaid heads.
Zacks Rank & Key Picks
UnitedHealth currently has a Zacks Rank #3 (Hold).
The Zacks Consensus Estimate for Enhabit’s 2025 earnings indicates more than 157% year-over-year surge. EHAB beat earnings estimates in three of the trailing four quarters and missed once, with an average surprise of 23.6%. The consensus mark for Enhabit’s 2025 revenues indicates 2.3% year-over-year growth.
The Zacks Consensus Estimate for Universal Health’s 2025 earnings indicates a 31.3% year-over-year increase. UHS beat earnings estimates in each of the trailing four quarters, with an average surprise of 15.2%. The consensus mark for Universal Health’s revenues implies 9.7% growth from the year-ago period.
The Zacks Consensus Estimate for ResMed’s current-year earnings implies a 13.7% improvement from the year-ago reported figure. RMD beat earnings estimates in each of the trailing four quarters, with an average surprise of 3%. The consensus mark for ResMed’s current-year revenues is pegged at $5.58 billion, which indicates an 8.4% year-over-year increase.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
UnitedHealth Q4 Earnings Beat on Strong Optum Rx, Offers 2026 Outlook
Key Takeaways
UnitedHealth Group Incorporated (UNH - Free Report) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.11, which beat the Zacks Consensus Estimate of $2.09. However, the bottom line declined 69% year over year.
Revenues rose 12% year over year to $113.2 billion. The top line marginally missed the consensus mark.
The quarterly earnings were aided by growth in commercial fee-based membership and the strength witnessed in Optum Rx. However, elevated medical costs and declining risk-based membership partially offset the positives.
The proposed 0.09% increase for 2027 Medicare Advantage payments from CMS was below analyst expectations, which might dampen the effects of the earnings beat and the outlook for 2026.
For the full-year 2025, revenues increased almost 12% year over year to $447.6 billion, but marginally missed the consensus mark. Adjusted earnings of $16.35 per share declined from $27.66 a year ago, but beat the consensus estimate by 0.3%.
UnitedHealth Group Incorporated Price, Consensus and EPS Surprise
UnitedHealth Group Incorporated price-consensus-eps-surprise-chart | UnitedHealth Group Incorporated Quote
Business Performance of UNH
UnitedHealth’s fourth-quarter premium of $88.8 billion increased from $76.5 billion a year ago but missed the consensus mark of $89 billion.
UNH’s adjusted medical care ratio (MCR) was 91.5% in the fourth quarter, which deteriorated 640 bps from the year-ago period. The metric was lower than the Zacks Consensus Estimate of 92.2%. MCR witnessed an increase due to reductions in Medicare funding and rising medical cost trend, which exceeded the pricing trend. Medical costs of $82 billion rose from $67 billion a year ago.
Fourth-quarter total operating costs of $112.8 billion escalated 21.3% year over year due to higher medical costs and operating costs. The figure came higher than our model estimate of $109.4 billion. The fourth-quarter 2025 adjusted operating cost ratio deteriorated to 13.5% from 11.9% a year ago.
UnitedHealth’s adjusted operating earnings declined 62.1% year over year to $3.1 billion in the fourth quarter.
UNH’s Business Platforms
Revenues of the health benefits business of UnitedHealth, UnitedHealthcare, advanced 17.5% year over year to $87.1 billion in the fourth quarter. The metric missed the Zacks Consensus Estimate of $87.3 billion. The UnitedHealthcare business catered to 49.8 million people as of Dec. 31, 2025, which grew 0.8% year over year. However, the figure missed the Zacks Consensus Estimate of 50.4 million.
Adjusted earnings from operations amounted to $472 million, down from $3 billion a year ago. The adjusted operating margin decreased to 0.5% from 4.1% a year ago.
Revenues in the Optum business line were $70.3 billion, which rose from $65.1 billion a year ago, due to strong contributions from Optum Rx. The figure surpassed the consensus mark of $67.6 billion. Optum’s adjusted earnings from operations declined to $2.7 billion from $5.2 billion a year ago. The adjusted operating margin of 3.8% decreased from 8%.
UNH’s Financial Position (As of Dec. 31, 2025)
UnitedHealth exited the fourth quarter with cash and short-term investments of $28.1 billion, which fell from the 2024-end level of $29.1 billion. Total assets of $309.6 billion increased from the $298.3 billion figure at 2024-end.
Long-term debt, less of current maturities, amounted to $72.32 billion, marginally down from the $72.36 billion figure as of Dec. 31, 2024. Short-term borrowings and the current maturities of long-term debt were $6.1 billion.
Total equity of $100.1 billion advanced from the 2024-end level of $98.3 billion.
UnitedHealth generated operating cash flows of $19.7 billion in 2025, which declined from the prior-year figure of $24.2 billion. For the full-year 2025, it made share repurchases worth $5.5 billion and paid dividends worth $7.9 billion.
UNH’s 2026 Outlook
Management projects revenues for 2026 above $439 billion, which is below the 2025 level due to planned right-sizing across operations. Adjusted EPS is expected to be at least $17.75 for 2026, indicating improving margins. It is higher than the Zacks Consensus Estimate of $17.61 now. Net margin is expected at around 3.6%, up from 2.7% in 2025.
It expects MCR to be 88.8% (± 50 bps) in 2026, down from 89.1% in 2025, while the operating cost ratio is likely to be 12.8% (± 50 bps). Tax rate is expected to be around 19.25%.
Operating cash flows are estimated to be $18 billion, down from the 2025 level. It expects to make repurchases of $2.5 billion and pay dividends worth $8 billion in 2026. Capex is estimated at $3.8 billion for the year.
Furthermore, it expects medical memberships to be within 46.945 – 47.495 million in 2026, with significant declines in commercial risk, Medicare Advantage and Medicaid heads.
Zacks Rank & Key Picks
UnitedHealth currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader Medical sector are Enhabit, Inc. (EHAB - Free Report) , Universal Health Services, Inc. (UHS - Free Report) and ResMed Inc. (RMD - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Enhabit’s 2025 earnings indicates more than 157% year-over-year surge. EHAB beat earnings estimates in three of the trailing four quarters and missed once, with an average surprise of 23.6%. The consensus mark for Enhabit’s 2025 revenues indicates 2.3% year-over-year growth.
The Zacks Consensus Estimate for Universal Health’s 2025 earnings indicates a 31.3% year-over-year increase. UHS beat earnings estimates in each of the trailing four quarters, with an average surprise of 15.2%. The consensus mark for Universal Health’s revenues implies 9.7% growth from the year-ago period.
The Zacks Consensus Estimate for ResMed’s current-year earnings implies a 13.7% improvement from the year-ago reported figure. RMD beat earnings estimates in each of the trailing four quarters, with an average surprise of 3%. The consensus mark for ResMed’s current-year revenues is pegged at $5.58 billion, which indicates an 8.4% year-over-year increase.